DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation
Abstract Background Recently, copy number alteration (CNA) of 9p24.1 were demonstrated in 10% of diffuse large b-cell lymphoma (DLBCL), with gene expression and mutation profiles that were similar to those of primary mediastinal large B-cell lymphoma (PMBCL). However, their CNA-based profile and cli...
Main Authors: | Xuemin Xue, Wenting Huang, Tian Qiu, Lei Guo, Jianming Ying, Ning Lv |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-07293-3 |
Similar Items
-
Loss of JAK1 Drives Innate Immune Deficiency
by: Agnieszka Witalisz-Siepracka, et al.
Published: (2019-01-01) -
A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation
by: Beiying An, et al.
Published: (2020-04-01) -
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
by: Na Luo, et al.
Published: (2018-06-01) -
The role of JAK2 abnormalities in hematologic neoplasms.
by: Mohammed Khalid Alabdulaali
Published: (2009-07-01) -
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01)